MURALI CHINTAGUMPALA to Male
This is a "connection" page, showing publications MURALI CHINTAGUMPALA has written about Male.
Connection Strength
1.150
-
Improving Time to Antibiotic Administration for Pediatric Oncology Patients With New-Onset Fever. JCO Oncol Pract. 2024 May; 20(5):725-731.
Score: 0.038
-
Ependymoma Presenting as a -Rim-Enhancing Lesion in the Brainstem. Pediatr Neurosurg. 2021; 56(5):455-459.
Score: 0.032
-
A single-arm study of systemic and sub-Tenon chemotherapy for Groups C and D intraocular retinoblastoma: A Children's Oncology Group study (ARET 0231). Pediatr Blood Cancer. 2020 09; 67(9):e28502.
Score: 0.029
-
Increased risk of pseudoprogression among pediatric low-grade glioma patients treated with proton versus photon radiotherapy. Neuro Oncol. 2019 05 06; 21(5):686-695.
Score: 0.027
-
Hypothyroidism after craniospinal irradiation with proton or photon therapy in patients with medulloblastoma. Pediatr Hematol Oncol. 2018 May; 35(4):257-267.
Score: 0.026
-
Ototoxicity and cochlear sparing in children with medulloblastoma: Proton vs. photon radiotherapy. Radiother Oncol. 2018 07; 128(1):128-132.
Score: 0.025
-
Progression-free survival of children with localized ependymoma treated with intensity-modulated radiation therapy or proton-beam radiation therapy. Cancer. 2017 Jul 01; 123(13):2570-2578.
Score: 0.023
-
Neuroendocrine Tumor of the Appendix in Children. J Pediatr Hematol Oncol. 2017 03; 39(2):97-102.
Score: 0.023
-
Multimodality Treatment of Pediatric Esthesioneuroblastoma. Pediatr Blood Cancer. 2016 Mar; 63(3):465-70.
Score: 0.021
-
Risk-Based Therapy for Localized Osteosarcoma. Pediatr Blood Cancer. 2016 Mar; 63(3):412-7.
Score: 0.021
-
A pilot study using carboplatin, vincristine, and temozolomide in children with progressive/symptomatic low-grade glioma: a Children's Oncology Group study?. Neuro Oncol. 2015 Aug; 17(8):1132-8.
Score: 0.021
-
Intensity-modulated radiotherapy (IMRT) in pediatric low-grade glioma. Cancer. 2013 Jul 15; 119(14):2654-9.
Score: 0.018
-
Long-term outcome of centrally located low-grade glioma in children. Cancer. 2013 Jul 15; 119(14):2630-8.
Score: 0.018
-
Renal and hepatic tumors in the neonatal period. Semin Fetal Neonatal Med. 2012 Aug; 17(4):216-221.
Score: 0.017
-
Leukaemia & cancer in neonates. Semin Fetal Neonatal Med. 2012 Aug; 17(4):183-184.
Score: 0.017
-
Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation. Pediatr Blood Cancer. 2011 Aug; 57(2):321-3.
Score: 0.015
-
Local control after craniospinal irradiation, intensity-modulated radiotherapy boost, and chemotherapy in childhood medulloblastoma. Cancer. 2011 Feb 01; 117(3):635-41.
Score: 0.015
-
Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma. Int J Radiat Oncol Biol Phys. 2010 Dec 01; 78(5):1445-50.
Score: 0.014
-
Cellular mesoblastic nephroma (infantile renal fibrosarcoma): institutional review of the clinical, diagnostic imaging, and pathologic features of a distinctive neoplasm of infancy. Pediatr Radiol. 2009 Oct; 39(10):1066-74.
Score: 0.014
-
Infantile fibrosarcoma: clinical and histologic responses to cytotoxic chemotherapy. Pediatr Blood Cancer. 2009 Jul; 53(1):23-7.
Score: 0.014
-
A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. Neuro Oncol. 2009 Feb; 11(1):33-40.
Score: 0.013
-
Changes mimicking new leptomeningeal disease after intensity-modulated radiotherapy for medulloblastoma. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):214-21.
Score: 0.013
-
A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group. J Neurooncol. 2006 Apr; 77(2):193-8.
Score: 0.011
-
Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer. J Clin Oncol. 2004 Nov 01; 22(21):4394-400.
Score: 0.010
-
The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma. Neuro Oncol. 2024 Oct 03; 26(10):1912-1920.
Score: 0.010
-
A Case Series of Children With Medulloblastoma Depicting the Disparities in Care and the Challenges in the Detection and Treatment of Pediatric Central Nervous System Tumors in Low-Resource Settings: A Case Study of Uganda. Pediatr Neurol. 2024 Dec; 161:67-72.
Score: 0.010
-
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors. J Clin Oncol. 2024 Aug 10; 42(23):2769-2779.
Score: 0.010
-
Late-onset lymphopenia during radiation is associated with an increased risk of tumor recurrence in newly diagnosed pediatric medulloblastoma. Pediatr Blood Cancer. 2024 Jul; 71(7):e31022.
Score: 0.010
-
Adaptive, behavioral, and emotional outcomes following postoperative pediatric cerebellar mutism syndrome in survivors treated for medulloblastoma. J Neurosurg Pediatr. 2024 Jun 01; 33(6):516-523.
Score: 0.010
-
Genetic susceptibility to cognitive decline following craniospinal irradiation for pediatric central nervous system tumors. Neuro Oncol. 2023 09 05; 25(9):1698-1708.
Score: 0.009
-
Comparison of neurocognitive and quality-of-life outcomes in pediatric craniopharyngioma patients treated with partial resection and radiotherapy versus gross-total resection only. J Neurosurg Pediatr. 2023 05 01; 31(5):453-462.
Score: 0.009
-
Predicting neurocognitive function in pediatric brain tumor early survivorship: The neurological predictor scale and the incremental validity of tumor size. Pediatr Blood Cancer. 2022 09; 69(9):e29803.
Score: 0.008
-
Kidney Preservation and Wilms Tumor Development in Children with Diffuse Hyperplastic Perilobar Nephroblastomatosis: A Report from the Children's Oncology Group Study AREN0534. Ann Surg Oncol. 2022 May; 29(5):3252-3261.
Score: 0.008
-
Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Cancer Cell. 2021 11 08; 39(11):1519-1530.e4.
Score: 0.008
-
Neighborhood Socioeconomic Deprivation and Mortality in Children with Central Nervous System Tumors. Cancer Epidemiol Biomarkers Prev. 2021 12; 30(12):2278-2285.
Score: 0.008
-
Durable Response to Larotrectinib in a Child With Histologic Diagnosis of Recurrent Disseminated Ependymoma Discovered to Harbor an NTRK2 Fusion: The Impact of Integrated Genomic Profiling. JCO Precis Oncol. 2021; 5.
Score: 0.008
-
Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1-mutant soft-tissue sarcoma of childhood. J Pathol. 2021 09; 255(1):52-61.
Score: 0.008
-
Long-term cognitive and academic outcomes among pediatric brain tumor survivors treated with proton versus photon radiotherapy. Pediatr Blood Cancer. 2021 09; 68(9):e29125.
Score: 0.008
-
Maternal and perinatal factors are associated with risk of pediatric central nervous system tumors and poorer survival after diagnosis. Sci Rep. 2021 05 17; 11(1):10410.
Score: 0.008
-
Cognitive Risk in Survivors of Pediatric Brain Tumors. J Clin Oncol. 2021 06 01; 39(16):1718-1726.
Score: 0.008
-
Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. Clin Cancer Res. 2021 05 15; 27(10):2879-2889.
Score: 0.008
-
Scoliosis in Children Treated With Photon Craniospinal Irradiation for Medulloblastoma. Int J Radiat Oncol Biol Phys. 2021 03 01; 109(3):712-717.
Score: 0.008
-
Disease Control and Patterns of Failure After Proton Beam Therapy for Rhabdomyosarcoma. Int J Radiat Oncol Biol Phys. 2021 03 01; 109(3):718-725.
Score: 0.008
-
Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. J Clin Oncol. 2021 03 01; 39(7):807-821.
Score: 0.008
-
Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). J Clin Oncol. 2021 03 01; 39(7):822-835.
Score: 0.008
-
Impact of SCID mouse gender on tumorigenicity, xenograft growth and drug-response in a large panel of orthotopic PDX models of pediatric brain tumors. Cancer Lett. 2020 11 28; 493:197-206.
Score: 0.007
-
Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol. 2020 06; 21(6):e305-e316.
Score: 0.007
-
Results of Treatment for Patients With Multicentric or Bilaterally Predisposed Unilateral Wilms Tumor (AREN0534): A report from the Children's Oncology Group. Cancer. 2020 08 01; 126(15):3516-3525.
Score: 0.007
-
Development of second primary tumors and outcomes in medulloblastoma by treatment modality: A Surveillance, Epidemiology, and End Results analysis. Pediatr Blood Cancer. 2020 08; 67(8):e28373.
Score: 0.007
-
Germline Elongator mutations in Sonic Hedgehog medulloblastoma. Nature. 2020 04; 580(7803):396-401.
Score: 0.007
-
Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials. Acta Neuropathol. 2020 02; 139(2):259-271.
Score: 0.007
-
Effect of sensorineural hearing loss on neurocognitive and adaptive functioning in survivors of pediatric embryonal brain tumor. J Neurooncol. 2020 Jan; 146(1):147-156.
Score: 0.007
-
Superior Intellectual Outcomes After Proton Radiotherapy Compared With Photon Radiotherapy for Pediatric Medulloblastoma. J Clin Oncol. 2020 02 10; 38(5):454-461.
Score: 0.007
-
Cognitive mediators of adaptive functioning outcomes in survivors of pediatric brain tumors treated with proton radiotherapy. Pediatr Blood Cancer. 2020 02; 67(2):e28064.
Score: 0.007
-
Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy: A Children's Oncology Group Study. J Clin Oncol. 2019 11 01; 37(31):2883-2891.
Score: 0.007
-
Patterns of failure and toxicity profile following proton beam therapy for pediatric bladder and prostate rhabdomyosarcoma. Pediatr Blood Cancer. 2019 11; 66(11):e27952.
Score: 0.007
-
Technical and anatomical factors affecting intra-arterial chemotherapy fluoroscopy time and radiation dose for intraocular retinoblastoma. J Neurointerv Surg. 2019 Dec; 11(12):1273-1276.
Score: 0.007
-
Prospective, longitudinal comparison of neurocognitive change in pediatric brain tumor patients treated with proton radiotherapy versus surgery only. Neuro Oncol. 2019 06 10; 21(6):809-818.
Score: 0.007
-
Adaptive functioning in pediatric brain tumor survivors: An examination of ethnicity and socioeconomic status. Pediatr Blood Cancer. 2019 09; 66(9):e27800.
Score: 0.007
-
Patterns of failure following proton beam therapy for head and neck rhabdomyosarcoma. Radiother Oncol. 2019 05; 134:143-150.
Score: 0.007
-
Pilot study of DNA methylation-derived neutrophil-to-lymphocyte ratio and survival in pediatric medulloblastoma. Cancer Epidemiol. 2019 04; 59:71-74.
Score: 0.007
-
Pediatric Bronchial Carcinoid Tumors: A Case Series and Review of the Literature. J Pediatr Hematol Oncol. 2019 01; 41(1):67-70.
Score: 0.007
-
Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol. 2018 06; 19(6):785-798.
Score: 0.006
-
Meta-analysis of the incidence and patterns of second neoplasms after photon craniospinal irradiation in children with medulloblastoma. Pediatr Blood Cancer. 2018 08; 65(8):e27095.
Score: 0.006
-
Umbilical metastasis (Sister Mary Joseph's nodule) in a child. Pediatr Radiol. 1998 Jan; 28(1):56-8.
Score: 0.006
-
A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas. Pediatr Blood Cancer. 2018 Feb; 65(2).
Score: 0.006
-
Local therapy to distant metastatic sites in stage IV rhabdomyosarcoma. Pediatr Blood Cancer. 2018 Feb; 65(2).
Score: 0.006
-
DNA methylation of a novel PAK4 locus influences ototoxicity susceptibility following cisplatin and radiation therapy for pediatric embryonal tumors. Neuro Oncol. 2017 Oct 01; 19(10):1372-1379.
Score: 0.006
-
Results of the First Prospective Multi-institutional Treatment Study in Children With Bilateral Wilms Tumor (AREN0534): A Report From the Children's Oncology Group. Ann Surg. 2017 09; 266(3):470-478.
Score: 0.006
-
Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study. Neuro Oncol. 2017 09 01; 19(9):1279-1280.
Score: 0.006
-
Attention, processing speed, and executive functioning in pediatric brain tumor survivors treated with proton beam radiation therapy. Radiother Oncol. 2017 07; 124(1):89-97.
Score: 0.006
-
Vitreous Seeds in Retinoblastoma: Clinicopathologic Classification and Correlation. Ophthalmology. 2017 10; 124(10):1540-1547.
Score: 0.006
-
Myofibroma in Infancy and Childhood. J Pediatr Hematol Oncol. 2017 04; 39(3):e136-e139.
Score: 0.006
-
Systemic neoadjuvant chemotherapy for Group B intraocular retinoblastoma (ARET0331): A report from the Children's Oncology Group. Pediatr Blood Cancer. 2017 Jul; 64(7).
Score: 0.006
-
Exploratory analysis of ERCC2 DNA methylation in survival among pediatric medulloblastoma patients. Cancer Epidemiol. 2016 10; 44:161-166.
Score: 0.006
-
Mixed neuronal-glial tumors (gangliogliomas) in children. Pediatr Neurosurg. 1996 Jun; 24(6):306-13.
Score: 0.006
-
Correlation of Insurance, Race, and Ethnicity with Pathologic Risk in a Controlled Retinoblastoma Cohort: A Children's Oncology Group Study. Ophthalmology. 2016 08; 123(8):1817-1823.
Score: 0.006
-
Pancytopenia with chromosomal fragility: vitamin B12 deficiency. J Pediatr Hematol Oncol. 1996 May; 18(2):166-70.
Score: 0.006
-
Preservation of KIT genotype in a novel pair of patient-derived orthotopic xenograft mouse models of metastatic pediatric CNS germinoma. J Neurooncol. 2016 05; 128(1):47-56.
Score: 0.005
-
Comparing Intelligence Quotient Change After Treatment With Proton Versus Photon Radiation Therapy for Pediatric Brain Tumors. J Clin Oncol. 2016 Apr 01; 34(10):1043-9.
Score: 0.005
-
Recurrent internal tandem duplications of BCOR in clear cell sarcoma of the kidney. Nat Commun. 2015 Nov 17; 6:8891.
Score: 0.005
-
Relapsed hepatoblastoma confined to the lung is effectively treated with pulmonary metastasectomy. J Pediatr Surg. 2016 Apr; 51(4):525-9.
Score: 0.005
-
Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients. J Neurooncol. 2015 Nov; 125(2):307-15.
Score: 0.005
-
Treatment of essential thrombocythemia with anagrelide. J Pediatr. 1995 Sep; 127(3):495-8.
Score: 0.005
-
Mucoepidermoid Carcinoma in Children: A Single Institutional Experience. Pediatr Blood Cancer. 2016 Jan; 63(1):27-31.
Score: 0.005
-
Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. J Clin Oncol. 2015 Aug 20; 33(24):2646-54.
Score: 0.005
-
Imaging Changes in Pediatric Intracranial Ependymoma Patients Treated With Proton Beam Radiation Therapy Compared to Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2015 Sep 01; 93(1):54-63.
Score: 0.005
-
Routine use of recombinant human bone morphogenetic protein-2 in posterior fusions of the pediatric spine and incidence of cancer. J Neurosurg Pediatr. 2015 Jul; 16(1):4-13.
Score: 0.005
-
Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nat Genet. 2015 Mar; 47(3):263-6.
Score: 0.005
-
Long-term disease control and toxicity outcomes following surgery and intensity modulated radiation therapy (IMRT) in pediatric craniopharyngioma. Radiother Oncol. 2015 Feb; 114(2):224-9.
Score: 0.005
-
A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study. Neuro Oncol. 2015 Feb; 17(2):303-11.
Score: 0.005
-
Outcomes and acute toxicities of proton therapy for pediatric atypical teratoid/rhabdoid tumor of the central nervous system. Int J Radiat Oncol Biol Phys. 2014 Dec 01; 90(5):1143-52.
Score: 0.005
-
Therapeutic implications of CD1d expression and tumor-infiltrating macrophages in pediatric medulloblastomas. J Neurooncol. 2014 Nov; 120(2):293-301.
Score: 0.005
-
Proton beam therapy versus conformal photon radiation therapy for childhood craniopharyngioma: multi-institutional analysis of outcomes, cyst dynamics, and toxicity. Int J Radiat Oncol Biol Phys. 2014 Oct 01; 90(2):354-61.
Score: 0.005
-
Secondary glioblastoma multiform in a patient with CHARGE syndrome and prior radiation therapy for medulloblastoma. Pediatr Hematol Oncol. 2014 May; 31(4):366-8.
Score: 0.005
-
A patient tumor-derived orthotopic xenograft mouse model replicating the group 3 supratentorial primitive neuroectodermal tumor in children. Neuro Oncol. 2014 Jun; 16(6):787-99.
Score: 0.005
-
Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma. Neuro Oncol. 2014 Jun; 16(6):848-55.
Score: 0.005
-
Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma. Pediatr Blood Cancer. 2014 Apr; 61(4):601-5.
Score: 0.005
-
Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res. 2013 Nov 15; 19(22):6305-12.
Score: 0.005
-
Integrated multimodal genetic testing of Ewing sarcoma--a single-institution experience. Hum Pathol. 2013 Oct; 44(10):2010-9.
Score: 0.005
-
Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas. Neuro Oncol. 2013 Jun; 15(6):759-66.
Score: 0.004
-
Implications of tumor location on subtypes of medulloblastoma. Pediatr Blood Cancer. 2013 Sep; 60(9):1408-10.
Score: 0.004
-
Hodgkin's disease associated with central pontine myelinolysis. Med Pediatr Oncol. 1993; 21(4):311-4.
Score: 0.004
-
Sinonasal teratocarcinosarcoma in an adolescent male. J Pediatr Hematol Oncol. 2012 Oct; 34(7):e304-7.
Score: 0.004
-
Maternal variation in EPHX1, a xenobiotic metabolism gene, is associated with childhood medulloblastoma: an exploratory case-parent triad study. Pediatr Hematol Oncol. 2012 Nov; 29(8):679-85.
Score: 0.004
-
Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001). J Neurooncol. 2012 Sep; 109(3):565-71.
Score: 0.004
-
Outcome of patients with pilocytic astrocytoma and leptomeningeal dissemination. Int J Radiat Oncol Biol Phys. 2012 Oct 01; 84(2):350-4.
Score: 0.004
-
Residual intraretinal retinoblastoma after chemoreduction failure. Arch Ophthalmol. 2012 Feb; 130(2):246-8.
Score: 0.004
-
Chronic relapsing thrombotic thrombocytopenic purpura in infants with large von Willebrand factor multimers during remission. J Pediatr. 1992 Jan; 120(1):49-53.
Score: 0.004
-
Mutations of PTCH1, MLL2, and MLL3 are not frequent events in hepatoblastoma. Pediatr Blood Cancer. 2012 Jun; 58(6):1006-7.
Score: 0.004
-
Outcomes of integrating genetics in management of patients with retinoblastoma. Arch Ophthalmol. 2011 Nov; 129(11):1428-34.
Score: 0.004
-
Low early ototoxicity rates for pediatric medulloblastoma patients treated with proton radiotherapy. Radiat Oncol. 2011 Jun 02; 6:58.
Score: 0.004
-
Essential thrombocythemia in a child: management with anagrelide. Am J Pediatr Hematol Oncol. 1991; 13(1):52-6.
Score: 0.004
-
Plasma proteome predicts chemotherapy response in osteosarcoma patients. Oncol Rep. 2011 Feb; 25(2):303-14.
Score: 0.004
-
Elevated expression of CXC chemokines in pediatric osteosarcoma patients. Cancer. 2011 Jan 01; 117(1):207-17.
Score: 0.004
-
High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma. Pediatr Blood Cancer. 2010 Jul 15; 55(1):149-52.
Score: 0.004
-
A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo. Neuro Oncol. 2010 Jun; 12(6):580-94.
Score: 0.004
-
Medulloblastoma and juvenile pilocytic astrocytoma presenting as synchronous primary brain tumors in a child: case report. J Neurosurg Pediatr. 2010 Feb; 5(2):149-54.
Score: 0.004
-
Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma. Neuro Oncol. 2009 Jun; 11(3):292-300.
Score: 0.003
-
Neuropsychological outcome following intensity-modulated radiation therapy for pediatric medulloblastoma. Pediatr Blood Cancer. 2008 Aug; 51(2):275-9.
Score: 0.003
-
Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol. 2008 Aug 01; 26(22):3749-55.
Score: 0.003
-
Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma. Mol Cancer Res. 2008 Jun; 6(6):937-46.
Score: 0.003
-
Local control after intensity-modulated radiotherapy for head-and-neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):173-7.
Score: 0.003
-
Results of treatment of patients with superficial facial rhabdomyosarcomas on protocols of the Intergroup Rhabdomyosarcoma Study Group (IRSG), 1984-1997. Pediatr Blood Cancer. 2008 May; 50(5):958-64.
Score: 0.003
-
Direct orthotopic transplantation of fresh surgical specimen preserves CD133+ tumor cells in clinically relevant mouse models of medulloblastoma and glioma. Stem Cells. 2008 Jun; 26(6):1414-24.
Score: 0.003
-
Intensity-modulated radiation therapy in childhood ependymoma. Int J Radiat Oncol Biol Phys. 2008 Jul 15; 71(4):987-93.
Score: 0.003
-
Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma. Int J Radiat Oncol Biol Phys. 2008 Mar 01; 70(3):782-7.
Score: 0.003
-
Expression of oligodendroglial differentiation markers in pilocytic astrocytomas identifies two clinical subsets and shows a significant correlation with proliferation index and progression free survival. J Neurooncol. 2008 Jan; 86(2):183-90.
Score: 0.003
-
Anaplastic ganglioglioma arising from a Lhermitte-Duclos-like lesion. Case report. J Neurosurg. 2007 Aug; 107(2 Suppl):137-42.
Score: 0.003
-
Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study. J Clin Oncol. 2007 Jul 20; 25(21):3130-6.
Score: 0.003
-
A single institution experience with pediatric nasopharyngeal carcinoma: high incidence of toxicity associated with platinum-based chemotherapy plus IMRT. J Pediatr Hematol Oncol. 2007 Jul; 29(7):500-5.
Score: 0.003
-
Extensively necrotic retinoblastoma is associated with high-risk prognostic factors. Arch Pathol Lab Med. 2006 Nov; 130(11):1669-72.
Score: 0.003
-
Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006 Oct; 7(10):813-20.
Score: 0.003
-
Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol. 2006 Apr 20; 24(12):1924-31.
Score: 0.003
-
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol. 2006 Feb; 76(3):313-9.
Score: 0.003
-
Prenatal presentation and outcome of children with pleuropulmonary blastoma. J Pediatr Surg. 2006 Jan; 41(1):66-71.
Score: 0.003
-
Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res. 2005 Sep 15; 65(18):8142-50.
Score: 0.003
-
Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol. 2005 Aug 20; 23(24):5511-9.
Score: 0.003
-
A homozygous mutation in MSH6 causes Turcot syndrome. Clin Cancer Res. 2005 Jul 01; 11(13):4689-93.
Score: 0.003
-
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98). Cancer. 2005 Jan 01; 103(1):133-9.
Score: 0.003
-
Expression analysis of juvenile pilocytic astrocytomas by oligonucleotide microarray reveals two potential subgroups. Cancer Res. 2005 Jan 01; 65(1):76-84.
Score: 0.003
-
White matter lesions detected by magnetic resonance imaging after radiotherapy and high-dose chemotherapy in children with medulloblastoma or primitive neuroectodermal tumor. J Clin Oncol. 2004 Nov 15; 22(22):4551-60.
Score: 0.002
-
Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol. 2004 Aug 15; 22(16):3357-65.
Score: 0.002
-
Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol. 2004 Mar 15; 22(6):984-93.
Score: 0.002
-
Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chromosomes Cancer. 2004 Jan; 39(1):11-21.
Score: 0.002
-
Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J Natl Cancer Inst. 2003 May 07; 95(9):669-74.
Score: 0.002
-
Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy. Cancer. 2003 May 01; 97(9 Suppl):2374-80.
Score: 0.002
-
Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin Cancer Res. 2002 Jul; 8(7):2202-9.
Score: 0.002
-
Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys. 2002 Mar 01; 52(3):599-605.
Score: 0.002
-
Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. Am J Med Genet. 2001 Jul 22; 102(1):11-7.
Score: 0.002
-
Neoplasms in neurofibromatosis 1 are related to gender but not to family history of cancer. Genet Epidemiol. 2001 Jan; 20(1):75-86.
Score: 0.002
-
Multifocal osteosarcoma: an unusual presentation. J Pediatr Hematol Oncol. 1999 Jan-Feb; 21(1):58-62.
Score: 0.002
-
Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura. Am J Hematol. 1998 Apr; 57(4):293-302.
Score: 0.002
-
Clear cell sarcoma of the kidney: an unusual presentation and review of the literature. J Pediatr Hematol Oncol. 1998 Mar-Apr; 20(2):165-8.
Score: 0.002
-
Primary malignant rhabdoid tumor of the central nervous system. Ultrastruct Pathol. 1997 Jul-Aug; 21(4):361-8.
Score: 0.001
-
Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood. Ultrastruct Pathol. 1997 Jul-Aug; 21(4):369-78.
Score: 0.001
-
Malignant melanoma of soft parts involving the head and neck region: review of literature and case report. Ultrastruct Pathol. 1995 Sep-Oct; 19(5):395-400.
Score: 0.001
-
Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura. Blood. 1994 Jul 15; 84(2):490-7.
Score: 0.001